Clinical Trials Browser

Patients With Any Advanced Solid Tumors

NCT01314105 2025-02-13

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Phase 1 Completed

19 enrolled 21 charts

Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

NCT01346540 2025-02-12

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Phase 1 Completed

16 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02300298 2025-02-11

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Phase 1 Completed

10 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02182219 2025-01-22

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Phase 1 Completed

21 enrolled

Genitourinary

Prostatic Neoplasms

NCT02225405 2024-05-08

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Phase 1 Completed

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02668393 2021-01-29

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

Phase 1 Completed

14 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02619162 2019-07-23

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

Phase 1 Completed

25 enrolled

Breast

Breast Neoplasms

NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Phase 1 Completed

30 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Phase 1 Completed

21 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

NCT01349296 2016-05-20

BARIS

Phase 1 Completed

18 enrolled

Other solid neoplasm

Solid Tumors

NCT01594125 2016-02-12

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

Phase 1 Completed

30 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01684111 2016-01-18

VENUS-1

Phase 1 Completed

7 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01683682 2015-01-26

VENUS-2

Phase 1 Completed

8 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00715403 2014-12-02

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Phase 1 Completed

41 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT02182102 2014-07-18

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

Phase 1 Completed

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02182128 2014-07-18

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Phase 1 Completed

24 enrolled

Tumor-Agnostic

Neoplasms

NCT02182206 2014-07-18

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

Phase 1 Completed

50 enrolled

Tumor-Agnostic

Neoplasms

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Phase 1 Completed

61 enrolled

Other solid neoplasm

Malignant Solid Tumour

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

Phase 1 Completed

28 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

PEMBIB

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

BARIS

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

VENUS-1

VENUS-2

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors